Roquefort Therapeutics PLC (LSE:ROQ) Chairman Stephen West speaks to Proactive London about LYRAMID, their research and development subsidiary which has identified lead compounds it will use for laboratory experiments to test their effectiveness in modifying properties of cancer cells.
Midkine is a growth factor believed to play a key role in disease development, further work is currently underway to gather more data on the ability of these drug candidates to modify midkine expression.
LYRAMID is exploring the use of midkine inhibitors to reverse resistance to cancer immunotherapy drugs such as checkpoint inhibitors.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that nothing posted on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is…
In exchange for publishing services rendered by the Company on behalf of the persons named herein, including the promotion by the Company of in any Site Content, the Company shall receive from such issuer an annual cash sum…
FOR OUR FULL DISCLAIMER, CLICK HERE